In a move poised to shake up the pharmaceutical landscape, the U.S. Federal Trade Commission (FTC) is preparing to take legal action against UnitedHealth, Cigna, and CVS Health. These healthcare giants, who act as intermediaries in negotiating drug prices, are under scrutiny for their role in the pricing of essential medications like insulin, according to an insider.
These companies control the largest pharmacy benefit managers (PBMs) and are now being investigated for the rebates they negotiate with drug manufacturers. These rebates, often tied to volume-based discounts, have a significant impact on drug pricing and accessibility.
CVS has announced its intention to mount a robust defense, while UnitedHealth has opted for silence, and Cigna has yet to comment.
A CVS spokesperson stated, “Any action that limits the use of these PBM negotiating tools would reward the pharmaceutical industry and return the market to a broken state, leaving American businesses and patients at the mercy of the prices drugmakers set.”
The FTC’s probe extends beyond PBMs to include drug manufacturers, particularly those producing insulin. The key players in this arena are Sanofi, Novo Nordisk, and Eli Lilly. Sanofi maintains that its pricing practices are lawful and focused on patient accessibility. Novo and Lilly have not provided immediate responses.
President Biden’s Inflation Reduction Act capped insulin prices for Medicare recipients at $35 per month, but this cap does not benefit those with private insurance or no insurance at all. A survey revealed that Americans without health insurance still pay an average of $98 for Eli Lilly’s generic insulin, despite the company’s pledge to lower prices.
In 2023, about 8.4 million Americans with diabetes relied on insulin, as reported by the American Diabetes Association. Insulin remains crucial for managing both type 1 and type 2 diabetes.
An interim FTC report released on Tuesday highlighted the dominant role of the three major PBMs, who manage 79% of U.S. prescription drug claims. The report criticized these companies for leveraging their position to increase profits at the expense of smaller pharmacies and consumers. Unsurprisingly, UnitedHealth’s Optum, CVS Health’s CVS Caremark, and Cigna’s Express Scripts have contested the report’s conclusions.
